Biogen (BIIB) Stock Forecast & Price Target
Score
Biogen Inc. price target
| BIIB | |
|---|---|
| Low | $175.00 |
| Average | $255.00 |
| High | $300.00 |
| Upside vs current price | +0.6% |
The average target of $255.00 is +0.6% versus the current BIIB price of $253.40.
Biogen Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 4 |
| Buy | 21 |
| Hold | 10 |
| Sell | 1 |
| Strong sell | 0 |
| Consensus | Buy |
36 analysts cover BIIB.
Biogen Inc. EPS and revenue estimates
Published annual figures for BIIB on this page are 2026 EPS $12.47, 2027 EPS $16.27. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $12.47 | $10.58B |
| 2027 | $16.27 | $10.78B |
Is Biogen Inc. a buy or sell?
Of the 36 analysts covering Biogen Inc., 25 rate it a buy (4 strong buy and 21 buy), 10 rate it a hold, and 1 rates it a sell (1 sell and 0 strong sell).
The BIIB consensus label is Buy, beside 25 buy-side ratings and 1 sell-side ratings.
The average target of $255.00 implies +0.6% versus the current price of $253.40.
The BIIB rating block is 36 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Biogen Inc. forecast
A wide spread is the story on BIIB. Targets run from $175.00 to $300.00, with $255.00 as the average.
The gap from the $253.40 price to the BIIB average is +0.6%.
The BIIB rating mix is lopsided rather than split: 25 of 36 analysts are on the buy side, 10 are at hold, and 1 is on the sell side, and the published consensus is Buy.
the Biogen Inc. has seen more upgrades (3) than downgrades (0) lately.
Month by month, the BIIB average target is higher ($268.11) than the quarterly average ($259.64).
the Biogen Inc. is followed by 36 analysts, so the range matters more than any one target.
Biogen Inc. forecast questions
What is the BIIB price target?
The published range for BIIB is $175.00 to $300.00, with an average of $255.00. That average is +0.6% versus the current price of $253.40.
Is Biogen Inc. a buy or sell?
Of the 36 analysts covering Biogen Inc., 25 rate it a buy, 10 rate it a hold, and 1 rates it a sell. The consensus is Buy, leaving BIIB at 25 buy ratings, 10 holds, and 1 sells.
What is the EPS estimate for Biogen Inc.?
Analyst EPS estimates for Biogen Inc.: 2026 $12.47, 2027 $16.27.
What is the revenue estimate for Biogen Inc.?
Analyst revenue estimates for Biogen Inc.: 2026 $10.58B, 2027 $10.78B.
How many analysts cover BIIB?
36 analysts cover BIIB. Their consensus on BIIB is Buy, across those 36.